Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials
Ryan C, Leonardi CL, Krueger JG et al.
Ustekinumab and briakinumab, monoclonal antibodies to the shared p40 subunit of interleukin-12 (IL-12) and IL-23, are effective for the treatment of chronic plaque psoriasis; however, preliminary reports suggest that major adverse cardiovascular events (MACEs) occur more frequently in psoriasis patients receiving these agents than in those who do not. In this meta-analysis of 22 randomized controlled trials, 10 of 3179 patients receiving anti-IL-12/-23 therapies experienced MACEs compared with none of 1474 patients receiving placebo. This excess risk was non-significant, but the power to detect a difference was limited.